These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 8846383)
41. Update on oral hypoglycemics (continuing education credit). White JR J Pract Nurs; 1994 Mar; 44(1):24-31; quiz 31-3. PubMed ID: 8158562 [No Abstract] [Full Text] [Related]
42. Adverse drug reaction: a possible case of glimepiride-induced syndrome of inappropriate antidiuretic hormone secretion. Adachi H; Yanai H Diabetes Metab; 2015 Apr; 41(2):176-7. PubMed ID: 25559655 [No Abstract] [Full Text] [Related]
43. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313 [No Abstract] [Full Text] [Related]
44. [Clinical evaluation of a new sulfonylurea derivative, preparation SPC-703, based on a 5-year observation]. Horoszek-Maziarz S; Berliński E; Jaromczyk-Slisz J; Rachoń K; Wójcikowski C; Słomiński M; Orłowska-Kunikowska E; Krupa-Wojciechowska B Pol Tyg Lek; 1985 May; 40(18):516-8. PubMed ID: 3892514 [No Abstract] [Full Text] [Related]
45. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes. Charbonnel B Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387 [No Abstract] [Full Text] [Related]
48. Initial management of glycemia in type 2 diabetes. Banarer S N Engl J Med; 2003 Feb; 348(8):760-1; author reply 760-1. PubMed ID: 12594327 [No Abstract] [Full Text] [Related]
49. The second-generation sulfonylureas: change or progress? Kreisberg RA Ann Intern Med; 1985 Jan; 102(1):125-6. PubMed ID: 3966729 [No Abstract] [Full Text] [Related]
50. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418 [No Abstract] [Full Text] [Related]
51. Follow-up of intensive glucose control in type 2 diabetes. Petrie JR N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672 [No Abstract] [Full Text] [Related]
52. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Bressler R; Johnson DG Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543 [TBL] [Abstract][Full Text] [Related]
53. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes]. Rustenbeck I Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335 [TBL] [Abstract][Full Text] [Related]
54. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035 [TBL] [Abstract][Full Text] [Related]
55. A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm. Riddle MC Diabetes Care; 2019 Dec; 42(12):2161-2163. PubMed ID: 31748210 [No Abstract] [Full Text] [Related]
56. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro]. Nauck MA Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041 [No Abstract] [Full Text] [Related]
57. [Evaluation of a new sulfonylurea, glipizide, in the treatment of diabetes mellitus]. Ninni M; Castelletta L Minerva Med; 1973 Oct; 64(71):3725-31. PubMed ID: 4588364 [No Abstract] [Full Text] [Related]
58. Drugs for type 2 diabetes. Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949 [No Abstract] [Full Text] [Related]
59. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Johnson JL; Wolf SL; Kabadi UM Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835 [TBL] [Abstract][Full Text] [Related]
60. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Malesker MA Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]